TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05773157

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Online Modules
Description: Participants receive modules to improve responsive feeding practices of caregivers
Study: NCT05424484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-Gripping Resorbable Mesh
Description: Self-Gripping Resorbable Mesh used for suture line reinforcement after midline laparotomy in clean and clean-contaminated fields (CDC Classification I and II).
Study: NCT05278208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUTATHERA® (Lutetium Lu 177 dotatate)
Description: Lutathera: IV administration maximum dose of 200 mCi once every 8 weeks (one cycle) for total of 4 cycles (8 months)
Study: NCT06196879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verekitug (UPB-101)
Description: Verekitug (UPB-101) formulated solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verekitug (UPB-101)
Description: Verekitug (UPB-101) formulated solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verekitug (UPB-101)
Description: Verekitug (UPB-101) formulated solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Verekitug (UPB-101) matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Verekitug (UPB-101) matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Verekitug (UPB-101) matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Verekitug (UPB-101) matching placebo
Study: NCT05153434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARD-101
Description: Twice Daily, Oral Administration
Study: NCT06494774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1815368
Description: BI 1815368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1815368
Description: BI 1815368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1815368
Description: BI 1815368

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 1815368
Description: Placebo matching BI 1815368
Study: NCT05062044

Intervention type: DIETARY_SUPPLEMENT
Intervention: Multivitamins (Elevit, BAY987808)
Description: Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Multivitamins (Elevit, BAY987808)
Description: Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Multivitamins (Elevit, BAY2906300)
Description: Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Multivitamins (Elevit, BAY2906300)
Description: Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.

Intervention type: DRUG
Intervention: Multivitamins (Elevit, BAY987386)
Description: Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.

Intervention type: DRUG
Intervention: Multivitamins (Elevit, BAY987386)
Description: Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Folic acid
Description: Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.
Study: NCT05985343

Intervention type: DRUG
Group type: OTHER
Intervention: Neostigmine / Glycopyrrolate
Description: Patients will receive standard of care for reversal of neuromuscular blockade

Intervention type: DRUG
Group type: OTHER
Intervention: Sugammadex
Description: Patients will receive sugammadex for reversal of neuromuscular blockade
Study: NCT05197790

Intervention type: DEVICE
Group type: OTHER
Intervention: FDA approved pulse oximeter and DOVE device prototype
Description: The objective is to assess reasonable detection of hypoxic episodes
Study: NCT04745520

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rib fixation
Description: Rib fixation is performed by a senior surgeon. The patient is under general anesthesia. A thoracotomy focused on the fracture is performed to optimize access to the rib to be repaired. Video-assisted thoracic surgery (VATS) can be performed to better localize rib fractures. Significant muscle division is avoided. Removal of the periosteum is not required. The broken rib segments are approximated with forceps and the medical devices are used to fix the fracture. The medical devices are implemented according to the manufacturers' recommendations. The goal is to stabilize the chest wall. It is not useful to fix all fractures to stabilize the wall. A chest tube can be placed at the end of the operation.~Medical devices~The following medical devices can be used:~* MatrixRIB™, De Puy Synthes Companies, Zuchwill, Switzerland~* STRATOS™, MedXpert GmbH, Heitersheim, Germany~* NiTi Fixing PlatesTM, IAWAI, Yandzhou, China

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesia
Description: Epidural analgesia is continuing for 24 to 72 hours post-randomization to maximize outcome benefits. Afterwards, paracetamol, NSAID and/or opioid treatment are used according to pain severity. In case of opioid use, morphine treatment is preferred. However, other opioid drugs or doses can be considered to better customize the treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analgesia
Description: Epidural analgesia is continuing for 24 to 72 hours post-randomization to maximize outcome benefits. Afterwards, paracetamol, NSAID and/or opioid treatment are used according to pain severity. In case of opioid use, morphine treatment is preferred. However, other opioid drugs or doses can be considered to better customize the treatment.
Study: NCT06362421

Intervention type: GENETIC
Intervention: Pre-Radiation Dental Evaluation/Sample Collection
Description: Collection of saliva samples and mouth swabs and pre-cancer dental evaluation by study staff. Unstimulated saliva will be collected then a buccal swab sample will be obtained. Participants will be asked to rinse their mouth with water, wait 10 minutes, then 1-2 mL of unstimulated saliva will be captured into sterile centrifuge tube. Next, a buccal swab sample will be collected using a sterile cotton swab and immediately placed in a transport tube containing buffer (Tris with low EDTA)

Intervention type: OTHER
Intervention: Pre-Study Visit
Description: Collection of vital signs, medical history and current medications

Intervention type: OTHER
Intervention: Pre-Study Visit
Description: Collection of vital signs, medical history and current medications

Intervention type: GENETIC
Intervention: Oral Medicine Consultation Visit/Sample Collection
Description: Collection of saliva samples and mouth swab, complete oral medicine consultation by study staff. Unstimulated saliva will be collected then a buccal swab sample will be obtained. Participants will be asked to rinse their mouth with water, wait 10 minutes, then 1-2 mL of unstimulated saliva will be captured into sterile centrifuge tube. Next, a buccal swab sample will be collected using a sterile cotton swab and immediately placed in a transport tube containing buffer (Tris with low EDTA)
Study: NCT05836220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLS240
Description: Participants will receive intravenous (IV) PLS240 three times per week for 27 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive intravenous (IV) placebo, containing no active drug, three times per week for 27 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-Label Extension PLS240
Description: Participants will receive intravenous (IV) PLS240 three times per week for a maximum of 26 weeks.
Study: NCT06418204

Intervention type: OTHER
Intervention: Non-interventional Study
Description: Non-interventional study
Study: NCT05050084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Anti-androgen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Anti-androgen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buserelin
Description: GnRH agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buserelin
Description: GnRH agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buserelin
Description: GnRH agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Anti-androgen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: GnRH antagonist
Study: NCT06071117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses (VR)
Description: Children allocated to this group will be distracted using VR glasses during dental treatment which is an individual headset that has earphones incorporated. Age-appropriate cartoons and movies will be shown to the children. The VR glasses will be then introduced to the children. The children will be given time to accommodate with the device before starting the procedure. The VR glasses will be applied during the dental examination and treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White noise
Description: Wireless kids' headphones will be introduced to the children allocated to this group. They will be given some time to accommodate with the headphones. Then, the white noise will be played and children will be asked to concentrate on the music during the procedure.~White noise stimulus will be set at 70 decibels, within the normal conversation volume range and below what is considered harmful to hearing. The white noise of rain sound, managed with an iPhone application called Muse. The decibel level of white noise will be calibrated using a portable digital sound level meter

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Basic behavior management techniques
Description: Children allocated to this group will be managed by the basic behavior guidance techniques: (Tell-Show-Do). No adjunctive distraction tool will be used.
Study: NCT03952962

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abbott Laboratories Infinity™ implantable deep brain stimulation system
Description: Deep brain stimulation (DBS) refers to the process of delivering an electrical current to a precise location in the brain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abbott Laboratories Infinity™ implantable deep brain stimulation system
Description: Deep brain stimulation (DBS) refers to the process of delivering an electrical current to a precise location in the brain.
Study: NCT05050084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: GnRH antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: GnRH antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: Anti-androgen
Study: NCT04452851

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BREATHE
Description: The on-demand handheld portable noninvasive positive pressure airway device unit generates BiPAP by using a built-in blower which intakes air from the nearby ambient. The BiPAP pressure functions as a virtual stent within the lungs of a user with COPD. The virtual stent opens the passageways within the user lungs. Once opened, the virtual stent facilitates gas exchange in order to relieve dyspnea. By temporarily facilitating this gas exchange, the user will quickly recover from dyspnea in order to resume regular activities.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BREATHE
Description: The on-demand handheld portable noninvasive positive pressure airway device unit generates BiPAP by using a built-in blower which intakes air from the nearby ambient. The BiPAP pressure functions as a virtual stent within the lungs of a user with COPD. The virtual stent opens the passageways within the user lungs. Once opened, the virtual stent facilitates gas exchange in order to relieve dyspnea. By temporarily facilitating this gas exchange, the user will quickly recover from dyspnea in order to resume regular activities.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BREATHE
Description: The on-demand handheld portable noninvasive positive pressure airway device unit generates BiPAP by using a built-in blower which intakes air from the nearby ambient. The BiPAP pressure functions as a virtual stent within the lungs of a user with COPD. The virtual stent opens the passageways within the user lungs. Once opened, the virtual stent facilitates gas exchange in order to relieve dyspnea. By temporarily facilitating this gas exchange, the user will quickly recover from dyspnea in order to resume regular activities.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiPAP
Description: BiPAP stands for Bilevel Positive Airway Pressure, and is very similar in function and design to a CPAP machine (continuous positive airway pressure). A BiPAP machine is a non-invasive form of therapy for patients suffering from sleep apnea.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: COPD Inhaler
Description: Inhaler medication to support quick relief from COPD symptoms
Study: NCT06319729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDD-2105
Description: A Chinese herbal medicine formula containing four granular herbs.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06442722

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DDH with capsulorrhaphy
Description: group will undergo capsulorrhaphy, a surgical procedure to tighten the hip capsule ,

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DDH without capsulorrhaphy
Description: group will not undergo capsulorrhaphy, a surgical procedure without tightness the hip capsule
Study: NCT05050084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: Anti-androgen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: GnRH agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: GnRH agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: GnRH agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Histrelin
Description: GnRH agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Histrelin
Description: GnRH agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Histrelin
Description: GnRH agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: GnRH agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: GnRH agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: GnRH agonist

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: GnRH antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: GnRH antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: GnRH antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: GnRH agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: GnRH agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: GnRH agonist
Study: NCT05296304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexarotene
Description: Orally every day starting at the dose of 150 mg/day flat dose. At Day 15, if the treatment is tolerated, patients will escalate the dose of bexarotene to 300 mg/day, and that dose will remain constant during the rest of the study.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Skin Electron Beam (TSEB)
Description: At Day 21, if the bexarotene has shown to be tolerated, patients will receive the first dose of TSEB (2 Gy x 2).
Study: NCT06287073

Intervention type: DRUG
Intervention: JARDIANCE®
Description: JARDIANCE®
Study: NCT05238753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive electromagnetic stimulation
Description: Non-invasive bilateral electromagnetic stimulation of the phrenic nerve
Study: NCT04784078

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Angiography and Intervention
Description: Transradial access puncture site

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary Angiography and Intervention
Description: Transradial access puncture site
Study: NCT04852731

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Description: Injected cardiac MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: Blood collection (including genetics at the inclusion visit)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: Blood collection (including genetics at the inclusion visit)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: Blood collection (including genetics at the inclusion visit)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: Blood collection (including genetics at the inclusion visit)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: Blood collection (including genetics at the inclusion visit)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prolongation of the MRI examination
Description: Prolongation of the MRI examination (4D flow sequence ; about 10 min)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prolongation of the MRI examination
Description: Prolongation of the MRI examination (4D flow sequence ; about 10 min)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prolongation of the MRI examination
Description: Prolongation of the MRI examination (4D flow sequence ; about 10 min)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prolongation of the MRI examination
Description: Prolongation of the MRI examination (4D flow sequence ; about 10 min)
Study: NCT05316181

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: HIPEC perfusion, doxorubicin 35mg/m2 \& mitomycin 15 mg/m2, 41.5'C, 90 min.
Study: NCT05405764

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Porcine protein supplement
Description: Porcine protein supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control product maltodextrin supplement
Description: Maltodextrin supplementation
Study: NCT05348044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Res-ET intervention
Description: Remote IMST delivery on Resilience
Study: NCT03905941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 2000 mg/day will be used in this study. Metformin is a antihyperglycemic agent that is used as a first line medical therapy to treat type 2 diabetes mellitus. It is also used to prevent progression of impaired glucose tolerance. It decrease hepatic glucose production and increase insulin sensitivity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 2000 mg/day will be used in this study. Metformin is a antihyperglycemic agent that is used as a first line medical therapy to treat type 2 diabetes mellitus. It is also used to prevent progression of impaired glucose tolerance. It decrease hepatic glucose production and increase insulin sensitivity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral combined hormonal contraceptives
Description: Oral combined hormonal contraceptive (OCs) with a combination of ethinyl estradiol 20 mcg/norethindrone acetate 1 mg will be used in this study. OCs are normally used to prevent pregnancy by suppressing ovulation and to prevent endometrial hyperplasia by inducing regular withdrawal bleeding. OCs help control both clinical and biochemical hyperandrogenism in PCOS and are considered first line medical therapy until the age of menopause.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral combined hormonal contraceptives
Description: Oral combined hormonal contraceptive (OCs) with a combination of ethinyl estradiol 20 mcg/norethindrone acetate 1 mg will be used in this study. OCs are normally used to prevent pregnancy by suppressing ovulation and to prevent endometrial hyperplasia by inducing regular withdrawal bleeding. OCs help control both clinical and biochemical hyperandrogenism in PCOS and are considered first line medical therapy until the age of menopause.
Study: NCT06180122

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Duplex ultrasound
Description: Vascular ultrasound scan of the left common iliac vein

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Duplex ultrasound
Description: Vascular ultrasound scan of the left common iliac vein
Study: NCT05940415

Intervention type: BEHAVIORAL
Intervention: active surveillance
Description: active surveillance without prostate biopsy
Study: NCT06559007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5041 dose level 1
Description: Single dose of HRS-5041 orally administered
Study: NCT05254340

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Inulin ingestion is not being used to diagnose, treat, or prevent irritable bowel syndrome. Inulin is being used to study an individual's ability to ferment dietary fiber.
Study: NCT04972799

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: injection of autologous fat at Day 0 and injection of saline at 6 months
Description: injection into the intersphincter space

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: injection of saline at Day 0 and injection of autologous fat at 6 months
Description: injection into the intersphincter space
Study: NCT06607796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toluenesulfonamide (PTS) Intratumoral Injection
Description: intratumoral injection of toluenesulfonamide(PTS) to oligo lesions
Study: NCT06587633

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic procedure
Description: tSVFem injection + 3D scaffold placement